Susan Lee Lindquist, a prominent scientist at MIT and former Director of the Whitehead Institute, has died of cancer. “She was a risk-taker and an innovator,” said MIT’s David Page. “She believed that if we were not reaching for things beyond our grasp, we were not doing our job as researchers; if we were not constantly striving for that which we could only imagine, we were not fulfilling our obligations to society as scientists.”
This has been a rough year for biotech stocks in general, and the US presidential election isn’t helping matters. This month we’ve seen the key indexes slide as a Democratic success for Hillary Clinton appears more and more likely. Evidently, the prospect of increased regulatory activism doesn’t sit well with investors, though the biotech boom all played out under Obama.
Belgium’s Promethera Biosciences has added 10 million euros to its Series C. The biotech’s self-professed mission: To be a global leader in liver cell therapy (NASH). Investors: Vesalius Biocapital, SRIW, Fund+, MGI Global Fund (Mitsui & Co), Boehringer Ingelheim Venture Fund and SMS Investments.
Sweden’s Bonesupport has raised $37 million in equity and debt financing.
Looking to jump into the marketing fray over PARP inhibitors, Tesaro says that its contender niraparib has been accepted for review by the EMA. It’s already angling for a US approval after posting promising data.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription